Page 1,294«..1020..1,2931,2941,2951,296..1,3001,310..»

Turmeric: what are the benefits and is it good for you? – The Irish Times

Posted: October 30, 2019 at 1:48 pm

Have you noticed lattes, ice cream and smoothies with a tawny hue? That could be a sign of a not-so-secret ingredient: turmeric. The botanical is omnipresent in health food aisles, in the form of pills and powders.

Turmeric, native to South Asia, is one of the fastest-growing dietary supplements. In 2018, products racked up an estimated 300 million in sales in the United States, a more than sevenfold increase from a decade earlier, according to a report from Nutrition Business Journal.

Brightening up the pantries of many homes in India, the spice is interwoven into daily life, the cuisine, and cultural and healing traditions. A member of the ginger family, it has been used in ayurvedic medicine for thousands of years. Apply turmeric to wounds, and its believed to fight infection. Mix it with milk, and the mind calms. Tint the entrance of new homes with a paste to welcome prosperity.

Turmeric is auspicious and one of the most important herbs, said Anupama Kizhakkeveettil, a board member of the National Ayurvedic Medical Association.

Sliced open, or dried into a spice, the Curcuma longa plant imparts its amber colour and earthy, bitter flavour to food like curry. The active ingredient captured in many turmeric supplements is curcumin. Curcumin, along with the other curcuminoid compounds, compose only about 3 per cent of the dried spice.

And bottles will often say turmeric on the front but list curcumin in the ingredients.

Turmeric is hailed for helping a host of conditions: high cholesterol, hay fever, depression, gingivitis, premenstrual syndrome and even hangovers. In ayurvedic medicine, it is believed to act as an anti-viral, anti-bacterial and anti-parasitic, and has long been used to help with diabetes, pain, rheumatism, osteoarthritis, memory and skin conditions like eczema.

We use it for so many different conditions, its a time-tested herb, Kizhakkeveettil said. Unfortunately, our science doesnt fit into complete randomised controlled trials. That is alternative medicines biggest challenge.

Researchers sought to answer this by sifting through the available literature. In a 2017 paper in the Journal of Medicinal Chemistry, they concluded its fools gold. There are claims that it can cure everything, said Kathryn Nelson, a research assistant professor at the University of Minnesota and the studys lead author. To me, that is a red flag.

Dr Amit Garg, a professor of medicine at Western University in London, Ontario, knew about turmerics medicinal use because of his Indian heritage. He knew first hand of its rich cultural significance too: on his wedding day, his relatives rubbed the spice all over him because it is believed to be cleansing.

After seeing the effectiveness of curcumin, in smaller studies, Garg and his colleagues decided to test it on a larger scale in hopes it would make elective aortic surgery safer by reducing the risk of complications, which include heart attacks, kidney injury and death. In the randomised clinical trial that followed, about half of the 606 patients were administered 2,000 milligrams of curcumin eight times over for four days, while the others were given a placebo. It was a bit disappointing, but we couldnt demonstrate any benefit used in this setting, Garg said of the study, published last year in the Canadian Medical Association Journal.

In fact, there is not enough reliable evidence in humans to recommend turmeric or curcumin for any condition, according to the US National Center for Complementary and Integrative Health. Turmeric became a nutritional golden child partly because of its promise in laboratory studies cellular and animal. Some research indicates that both turmeric and curcumin, the active ingredient in turmeric supplements, have anti-inflammatory, antioxidant, anti-bacterial, anti-viral and anti-parasitic activity. But this has mostly been demonstrated in laboratory studies, and, in many cases, the benefits of preclinical research isnt observed in clinical trials.

According to Natural Medicines, a database that provides monographs for dietary supplements, herbal medicines, and complementary and integrative therapies, while some clinical evidence shows that curcumin might be beneficial for depression, hay fever, hyperlipidemia, ulcerative colitis, osteoarthritis and nonalcoholic fatty liver disease, its still too early to recommend the compound for any of these conditions.

And Natural Medicines has found there isnt enough good scientific evidence to rate turmeric or curcumins use for memory, diabetes, fatigue, rheumatoid arthritis, gingivitis, joint pain, PMS, eczema or hangovers.

Physicians say more research is needed. Dr Gary Small, a professor of psychiatry and biobehavioral sciences at the David Geffen School of Medicine at the University of California, Los Angeles, who studies curcumins effect on memory, sees a lot of therapeutic potential. He also states that existing research demonstrates curcumins biological effects.

What may be affecting curcumins efficacy, doctors say, is that it is poorly absorbed from the gastrointestinal tract. In Indian cooking, turmeric is usually heated in a fat, like oil, which can increase absorption. Certain supplement manufacturers are also taking steps to improve this curcumins bioavailability by combining the compound with other components. For instance, a chemical found in black pepper called piperine is sometimes added to curcumin supplements in proprietary blends to increase its absorption.

Researching curcumin can be challenging because some blends have better bioavailability than others, and varying amounts of the active ingredient. If you did the study over and over again but used slightly different preparations, you would probably have different results, said Dr Janet Funk, a professor of medicine at the University of Arizona College of Medicine, who studies curcumins effect on bone.

Still, even if absorption improved, curcumin would not have any biological effects, Nelson contends. Turmeric may still have health benefits, she said, but they just may be from another compound or combination of compounds.

Consuming it by mouth is safe, up to 2g of turmeric daily for a year, and 4g daily of curcumin for a month, according to Natural Medicines. Turmeric aficionados who also use it as a face mask can relax too; the database indicates it is most likely safe to apply to the skin.

Doctors recommend that patients tell a physician they are taking turmeric. High doses of turmeric and its isolated constituents can have some rather unpleasant side effects, including diarrhea and nausea. Curcumin may also interact with anti-coagulants and anti-platelets, antacids, and drugs used for chemotherapy and to control blood pressure. While the spice is considered safe in food, therapeutic doses should be avoided during pregnancy.

The US Food and Drug Administration does not test dietary supplements such as turmeric for safety and effectiveness but announced this year that it would improve oversight of the growing industry.

One study published in 2018 in Molecular Nutrition & Food Research, found that the cheaper the turmeric product, the more likely it was to have chemical compounds suggestive of synthetic curcumin; and products with turmeric root were more likely to have higher lead levels. One sample exceeded recommended limits for lead.

How about all those turmeric lattes? Doctorssay that sprinkling a little bit of the bitter spice into frothed milk doesnt have proven health benefits. But that doesnt mean it isnt delicious.

As for Garg, he is not closing the bottle cap on curcumin. To wit: he is in the middle of a randomised study with a different preparation and dosing to see if curcumin prevents the progression of kidney disease. There are still many promising things about curcumin and turmeric, he said. I remain open-minded. New York Times

Read this article:
Turmeric: what are the benefits and is it good for you? - The Irish Times

Posted in Integrative Medicine | Comments Off on Turmeric: what are the benefits and is it good for you? – The Irish Times

Reviewing Madrigal Pharmaceuticals Inc. (MDGL)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

Posted: October 30, 2019 at 1:46 pm

We will be contrasting the differences between Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) as far as profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows us the return on assets, return on equity and net margins of both companies.

Volatility & Risk

Madrigal Pharmaceuticals Inc.s current beta is 1.16 and it happens to be 16.00% more volatile than Standard & Poors 500. Brainstorm Cell Therapeutics Inc.s 1.19 beta is the reason why it is 19.00% more volatile than Standard & Poors 500.

Liquidity

Madrigal Pharmaceuticals Inc. has a Current Ratio of 45.8 and a Quick Ratio of 45.8. Competitively, Brainstorm Cell Therapeutics Inc.s Current Ratio is 1 and has 1 Quick Ratio. Madrigal Pharmaceuticals Inc.s better ability to pay short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Madrigal Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.

$150.5 is Madrigal Pharmaceuticals Inc.s average target price while its potential upside is 57.59%. Meanwhile, Brainstorm Cell Therapeutics Inc.s average target price is $9, while its potential upside is 147.25%. Based on the results shown earlier, Brainstorm Cell Therapeutics Inc. is looking more favorable than Madrigal Pharmaceuticals Inc., analysts view.

Insider & Institutional Ownership

Institutional investors held 98.9% of Madrigal Pharmaceuticals Inc. shares and 11.4% of Brainstorm Cell Therapeutics Inc. shares. Insiders held roughly 11.33% of Madrigal Pharmaceuticals Inc.s shares. Comparatively, Brainstorm Cell Therapeutics Inc. has 0.6% of its share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Madrigal Pharmaceuticals Inc. has -22.56% weaker performance while Brainstorm Cell Therapeutics Inc. has 12.96% stronger performance.

Summary

Brainstorm Cell Therapeutics Inc. beats Madrigal Pharmaceuticals Inc. on 6 of the 10 factors.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The companys lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor- (THR-) agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It is also developing MGL-3745, which is in pre-clinical stage, a THR- agonist that is in preclinical trials. The company was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Link:
Reviewing Madrigal Pharmaceuticals Inc. (MDGL)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly

Posted in Pennsylvania Stem Cells | Comments Off on Reviewing Madrigal Pharmaceuticals Inc. (MDGL)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

Gene Therapy/Editing Series 1: A Brief Introduction To Gene Therapy – Seeking Alpha

Posted: October 30, 2019 at 1:46 pm

The recent approval of various gene therapies, for example, Luxturna and Zolgesma and high premium acquisitions of gene therapy companies have shifted the investor focus to this rapidly growing biotechnology field. In this series of review articles, I will review the gene therapy and gene editing field, starting first with the basics, including a brief overview of the history of the field and then moving on to some technical aspects, for example, the manufacturing, different methods of delivery, and then moving on to discussing the competitive landscape covering one genetic disease in each article.

Let's first define what is a gene? A gene is a sequence of nucleotides in DNA that encodes the synthesis of a gene product, which is usually a protein.

(F8 gene, mutations in the gene cause Hemophilia A)

Usually, the code (in the form of a specific arrangement of nucleotides or base pairs contained in the gene is used to form mRNA (called transcription) which acts as a messenger to take the code to the target organ of the body. The information stored in the mRNA is then used to encode and synthesize the target protein (called translation) which then performs its intended function in the body.

(Steps involved in synthesizing a protein from the code in a gene)

An estimated number of protein-coding genes in the human body is approximately 20,000 to 25,000, which has been revised down from the initial prediction of 100,000 genes. Each gene contains a number of base pairs, the number of which is estimated to range from about 50 million to 300 million in the human body. In general, a gene therapy can be broadly defined as delivering in a new gene into the cells to compensate for a defective gene. In gene therapy, a newly delivered gene can perform different functions; for example, it can either replace the defective gene or it can silence an abnormal gene.

(An example of a gene therapy using an adenoviral vector to deliver the normal gene)

While I will discuss the various steps and delivery systems in gene therapy in detail later, viruses like lentiviruses and adenovirus are most commonly used as vectors in gene therapy. It was as early as 1950s that scientists first discovered that a virus can be used to inject the DNA in the cells of the host. In 1970s, various experiments started to use viruses as delivery systems for genes in the human body. In 1971, Merril, et al conducted a scientific experiment showing that DNA could be injected into the human cells to fix a biological problem in the cells. This group of scientists extracted the cells from patients suffering from a disease called Galactosemia. It is important to note that this first gene therapy experiment involves the manipulation of genes ex vivo, that is in cells growing in a petri dish outside the body in a lab, which is easier to perform than manipulating the genes inside the human body, called in vivo approach. In 1972, a famous article in the prestigious journal Science by authors Friedman and Roblin first proposed that the gene therapy may ameliorate some human genetic diseases in the future. During the 1980s, various scientists like Martin Cline and French Anderson conducted experiments on using viruses as delivery vehicles for DNA in human or mouse cells. The first human trials of gene therapy started in the late 1980s and the results were reported in early 1990s. One of the first reported clinical studies in humans involved ex vivo modification of white blood cells taken from patients with advanced melanoma, using a retroviral vector to insert a gene coding for interleurkin-2 and injecting the genetically altered cells back into the patients. During the 1990s, French Anderson reported a successful clinical trial where a retroviral vector was used to transfer a gene encoding for adenosine deaminase, ADA in children with severe combined immunodeficiency, SCID. During the 1990s, most of the work in gene therapy continued in the therapeutic area of ADA-SCID.

Despite reasonably successful clinical results, the field of gene therapy suffered a serious setback in 1999. Jesse Gelsinger, an 18-year-old patient with a disease called ornithine transcarbamylase, OTC deficiency, which results due to a missing gene coding OTC died 4 days after receiving the gene therapy in a clinical trial conducted by the University of Pennsylvania due to massive immune response resulting in multi-organ failure. As a result, FDA put a suspension on various gene therapy clinical trials.

The field of gene therapy was then suspended for almost a decade. Glybera, a gene therapy was approved in Europe for reading a genetic disease, lipoprotein lipase deficiency in 2012. However, Glybera was a commercial failure after insurers in Europe were reluctant to pay for its expensive $1 million per patient tag. Finally, uniQure (QURE) the company that developed Glybera discontinued it.

Another commercial gene therapy failure was Strimvelis, a stem cell gene therapy to treat ADA-SCID. Despite its price being lower than Glybera ($665,000 per year), the therapy was not commercially successful in Europe and was sold by GlaxoSmithKline (GSK) to Orchard Therapeutics (ORTX) in 2018. In the US, the first approved gene therapy was Kymriah, an autologous CAR-T therapy to treat autologous lymphoblastic leukemia (ALL), which was developed by Novartis (NYSE:NVS).

After Kymriah, another autologous CAR-T therapy, Yeskarta (by Kite Pharmaceuticals) was approved by FDA to treat adult diffuse large B-cell lymphoma. Kite was later acquired by Gilead (NASDAQ:GILD). The first in vivo gene therapy approval in the US was Luxturna, an AAV gene therapy for patients with RPE 65 mutation-associated retinal dystrophy, which was developed by Spark Therapeutics which also was later acquired. Luxturna was another major milestone in the history of gene therapy as it resulted in a miraculous effect of restoring vision to children who were blind since birth. Recently, bluebird bio's (BLUE) gene therapy for transfusion-dependent beta-thalassemia was approved in Europe.

The developmental landscape of gene therapies can be summarized in some excellent figures from the journal Molecular Therapy published by the American Society of Gene and Cell Therapy (ASGCT). A group of researchers reviewed the medical literature and identified 336 gene therapies being developed for 138 different clinical indications covering 165 genetic targets excluding oncology. The researchers found that 74% of these 336 gene therapies were concentrated in five medical specialties, that is, hematology, endocrinology, neurosciences, cardiology, and ophthalmology. When classifying by different disease families, inborn errors of metabolism was the disease category with a majority of ongoing gene therapy trials.

(Landscape of gene therapy programs by organ system and disease area, source: Mol. Therapy)

When looking at specific clinical indications, Duchenne muscular dystrophy (DMD) was the clinical indication with the highest number of gene therapies being developed (15). HIV gene therapies (12 gene therapy programs) and hemophilia (11 gene therapy programs) took the second and third place respectively.

In terms of the number of gene therapy/editing programs being developed by a particular company or organization, Sangamo Therapeutics (SGMO) took the top spot (see the figure below).

(Landscape of gene therapy programs by company/organization, source: Mol. Therapy)

In conclusion, gene therapy has recovered from its earlier setbacks to emerge as one of the most innovative areas in biotechnology. In this first article of the series, I have provided a brief background about gene therapy, its history, and a broad top-down landscape. In the next article in the premium service, I will discuss various delivery systems for gene therapy.

A free two-week trial for the premium Marketplace service is open for another week only. Only 25 more spots left.

Disclosure: I am/we are long BLUE, ORTX, QURE, SGMO, AXGT, CRSP. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

See the rest here:
Gene Therapy/Editing Series 1: A Brief Introduction To Gene Therapy - Seeking Alpha

Posted in Pennsylvania Stem Cells | Comments Off on Gene Therapy/Editing Series 1: A Brief Introduction To Gene Therapy – Seeking Alpha

Anika Therapeutics, Inc. (ANIK)’s Stock Is Buy After Today’s Significant Increase – The Lamp News

Posted: October 30, 2019 at 1:45 pm

Investors sentiment decreased to 1.4 in Q2 2019. Its down 0.37, from 1.77 in 2019Q1. It turned negative, as 16 investors sold Anika Therapeutics, Inc. shares while 42 reduced holdings. 35 funds opened positions while 46 raised stakes. 13.49 million shares or 3.81% more from 13.00 million shares in 2019Q1 were reported.Moreover, South Dakota Council has 0.05% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK). 218,686 are held by Geode Cap Mgmt. Nelson Van Denburg And Campbell Wealth Group Ltd accumulated 13,306 shares or 0.1% of the stock. Oaktop Ii Lp owns 12,500 shares or 0.11% of their US portfolio. Thrivent For Lutherans holds 0% or 11,149 shares. 5,435 are owned by Jefferies Gru Limited Liability Corporation. Everence Cap Mngmt Incorporated accumulated 0.04% or 6,520 shares. Moreover, Deutsche Bank & Trust Ag has 0% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK). Aqr Limited Com reported 6,013 shares stake. Glenmede Co Na holds 54 shares. The Illinois-based Nuveen Asset Mgmt Llc has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). State Board Of Administration Of Florida Retirement owns 11,873 shares. Mark Sheptoff Finance Planning Ltd Limited Liability Company, a Connecticut-based fund reported 300 shares. Voloridge Invest Management Ltd holds 0.01% or 6,610 shares. Foundry Prtnrs Lc accumulated 0.09% or 54,915 shares.

The stock of Anika Therapeutics, Inc. (NASDAQ:ANIK) is a huge mover today! The stock increased 32.45% or $17.61 during the last trading session, reaching $71.88. About 498,503 shares traded or 144.39% up from the average. Anika Therapeutics, Inc. (NASDAQ:ANIK) has risen 39.72% since October 25, 2018 and is uptrending. It has outperformed by 39.72% the S&P500.The move comes after 6 months positive chart setup for the $990.72M company. It was reported on Oct, 25 by Barchart.com. We have $78.35 PT which if reached, will make NASDAQ:ANIK worth $89.16 million more.

More notable recent Anika Therapeutics, Inc. (NASDAQ:ANIK) news were published by: Benzinga.com which released: 42 Stocks Moving In Tuesdays Pre-Market Session Benzinga on July 30, 2019, also Seekingalpha.com with their article: Anika up 35% after Q2 beat Seeking Alpha published on July 25, 2019, Seekingalpha.com published: Pluristem Therapeutics and EDAP TMS among healthcare gainers; Align Technology among losers Seeking Alpha on July 25, 2019. More interesting news about Anika Therapeutics, Inc. (NASDAQ:ANIK) were released by: Benzinga.com and their article: The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lillys Nasal Low Blood Sugar Drug Benzinga published on July 25, 2019 as well as Finance.Yahoo.coms news article titled: Heres What Anika Therapeutics, Inc.s (NASDAQ:ANIK) P/E Is Telling Us Yahoo Finance with publication date: August 23, 2019.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $990.72 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 35.24 P/E ratio. The Companys orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the rest here:
Anika Therapeutics, Inc. (ANIK)'s Stock Is Buy After Today's Significant Increase - The Lamp News

Posted in South Dakota Stem Cells | Comments Off on Anika Therapeutics, Inc. (ANIK)’s Stock Is Buy After Today’s Significant Increase – The Lamp News

Stem Cell Therapy Market Trends, Secondary Research With Geron Corporation, Vericel Corporation, Pluristem Therapeutics, Cytori Therapeutics, Fate…

Posted: October 30, 2019 at 1:44 pm

Stem Cell Therapy Market research analysis and insights displayed in this report are very thoughtful for the businesses to make enhanced decisions, to build up better strategies about production, marketing, sales and promotion of a particular product. Stem Cell Therapy market report also takes into consideration several major factors such as revenue, cost, gross and gross margin while analysing market data. Various markets at local, regional and international level are thought of in this Stem Cell Therapy report. All this helps in extending their reach towards the success. The use of advanced tools and techniques applied for this report makes it the premium in the class. By understanding clients needs precisely, this report merges business and product information for the sustainable growth in the market. Geron Corporation, Vericel Corporation, Pluristem Therapeutics, Cytori Therapeutics, Fate Therapeutics are some players grooming the market.

Stem Cell Therapy Market is expected to reach USD 15.63 billion by 2025, from USD 7.72 billion in 2017 growing at a CAGR of 9.2% during the forecast period of 2018 to 2025. The Stem Cell Therapy market report contains data for historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025 (Updated values listed in sample report).

Get Sample of This Research Report:https://databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-therapy-market

Stem cell therapy is the therapy which uses stem cells for the treatment or prevention of a disease. Bone marrow transplant is the widely applicable therapy which is followed by umbilical cord blood. Research is going on to develop various sources (such as cord blood cells, bone marrow and skin) to use these cells for treatment of various disorders like neurodegenerative diseases and conditions such as heart disease, diabetes and other conditions. Some of the major players operating in the global stem cell therapy market are

Others: ViaCyte, Inc, AbbVie, Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc,, International Stem Cell Corporation, Aastrom Biosciences, Inc., Advanced Cell Technology, Cryo Cell International, Cytori Therapeutics, Inc., Geron Corporation, and Invitrogen and others. The global stem cell therapy market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of the global stem cell therapy market for global, Europe, North America, Asia Pacific and South America.

Get TOC For Full Analysis Of Report:https://databridgemarketresearch.com/toc/?dbmr=global-stem-cell-therapy-market

Major Market Drivers and Restraints:

Drivers:

Restraints:

Segmentation:

The global stem cell therapy market is segmented based on

Type

Product

Application

End Users

Geographical Segments

On the basis of type, the market is segmented into

Allogeneic stem cell therapy

Autologous stem cell therapy

The allogeneic stem cell therapy segment is expected lead the market because of commercialization of allogeneic stem cell therapy products and wide application with easy scale up process.

Based on products, the market is segmented into

Adult stem cells

Human embryonic stem cells

Induced pluripotent stem cells and others

The adult stem cells accounts highest share in market due to ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Based on application, the market is segmented into

Musculoskeletal disorders

Wounds and injuries

Cardiovascular diseases

Surgeries

Gastrointestinal diseases, and other applications

The musculoskeletal disorders segment leads the market due to availability of stem cell-based products for the treatment of musculoskeletal disorders, high prevalence of musculoskeletal disorders and bone & joint diseases.

Based on end users, the market is segmented into

Therapeutic companies

Cell and tissues banks

Tools and reagent companies

Service companies

The growing number of stem cell donors, improved stem cell banking facilities and because of the research and development therapeutic companies held the largest share in stem cell therapy.

By Geography

North America (U.S., Canada, Mexico)

South America (Brazil, Argentina, Rest of South America)

Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe)

Asia-Pacific ( Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific)

Middle East & Africa (South Africa, Egypt, Saudi Arabia, United Arab Emirates, Israel, Rest of Middle East & Africa)

More:
Stem Cell Therapy Market Trends, Secondary Research With Geron Corporation, Vericel Corporation, Pluristem Therapeutics, Cytori Therapeutics, Fate...

Posted in New Mexico Stem Cells | Comments Off on Stem Cell Therapy Market Trends, Secondary Research With Geron Corporation, Vericel Corporation, Pluristem Therapeutics, Cytori Therapeutics, Fate…

Fusarium disease: Researchers race to save bananas from extinction – FoodNavigator.com

Posted: October 30, 2019 at 1:44 pm

Fusariumis spread by a fungus in contaminated soil called Fusarium oxysporum f. sp. cubense (Foc) and infected plant materials. The disease is allegedly spread by farm machinery from abroad or transmitted by traveling farm workers or tourists.

Some scientists claim with the onset of Fusarium disease banana cultivation cannot continue without major changesand there is now anewstrain of Foc, the Tropical Race 4 (TR4), which attacks Cavendish (banana plant) clones and a diverse range of otherbananavarieties.

In August 2019, authorities in Colombia declared a national emergencyafter confirming TR4 had reached Latin America. The Colombian Agricultural Institute (ICA) in Bogot closed four plantations in northern Colombia as a result.

The disease is already widespread in Asia and now Ecuador, Colombia, Costa Rica, and Guatemala are on high alert. A major outbreak of TR4 could ruin farmers and increase the cost of bananas globally.

Nicolas Roux, head of genetic resources, Bioversity International, a CGIAR not-for-profit research centre, part of the Scientifique Agropolis, in Montpellier, France, told FoodNavigator TR4 is a variant of Panama disease, which wiped out banana plantations across Latin America in the mid-20th century.

The industry recovered after it replaced the most widely cultivated banana variety at that time, the Gros Michel, with a new one, the Cavendish. The Cavendish is resistant to Panama disease and now dominates the export industry. But the development of the new strain means that is under threat.

We keep on telling the big multi-national food companies that we need more funding to cultivate other gene resistant bananas so that we dont just rely on the Cavendish for exports but they are not listening, said Roux.

CGIAR is a global research partnership for a food-secure future. Its science is carried out by 15 Research Centers in collaboration with hundreds of partners across the globe.

It was born out of a need to reduce rural poverty, increase food security, improve human health and nutrition, and ensure sustainable management of natural resources. It is unusual in that it is not part of an international political institution, such as the United Nations or the World Bank, and as such relies on funding from its members.

Roux said the longer-term solution to the TR4 problem is replacing the vulnerable plants with a resistant variety.

As an example, the Honduras Foundation for Agricultural Research in La Lima has spent decadesbreeding TR4-resistant bananas. But so far the results have not lived up to the Cavendish in properties such as taste and resistance to blemishes.

According to James Dale of the Queensland University of Technology in Brisbane, it has produced a modified version of Cavendish but it is still undergoing trials with plans to commercialize it in 2023.

A lot of it depends on the consumer but they need to be informed of the crisis. We can create other gene resistant varieties of bananas but it is a question of whether people will like the taste because it wont be the same as what they buy in the supermarkets today, said Roux.

As scientists we want to promote the different varieties of bananas in the world to inform the consumer about how there is more than just one (Cavendish) that we commonly see in the supermarkets.

They [the scientists] are working on the different varieties to protect them from extinction and making them disease resistant and will now expand this to other crops but it is a difficult task, because without consumer engagement there is no education. Only when consumers become aware of the issue at large can we promote awareness of the different varieties and they are the ones who can change the world.

We are trying to promote the consumption and biodiversity of bananas, but they are difficult to export because we only know of one type of banana. So much investment has been put into Cavendish which is easy to grow and export that the large corporate food companies dont want to change to a different variety.

We are talking a lot now about fair trade and GMO (genetically modified organism) but a lot depends on the consumer and case by case.

We need GMO for certain variants but a lot of consumers are trying to quash that. But if people want to keep the banana we have now affected by disease the only way is through GMO because they want to keep the same taste.

It also means the yield will be lower which means export prices dont rocket, which is important to us. But we need to let people know that there are different types of bananas out there.

Roux said in his day-to-day work at Bioversity International he coordinates MusaNet (Musa is the Latin name for bananas) a global network of Musa genetic resources and has a team of 20; where half are based in Montpellier working on characterisation, documentation, genomics and bioinformatics and half are based at the KU University of Leuven's Laboratory of Tropical Crop Improvement, in Belgium, where they have the worlds largest collection of bananas, with 1,600 varieties.

The collection falls under the umbrella of the United Nations as the Bioversity International Musa Germplasm Transit Centre (ITC). To preserve the samples, the bioengineers use a cold chamber containing test tubes with small banana plantlets of 3cm to 4cm and cryotanks with plant stem cells in liquid nitrogen at a temperature of -196C.

Everyone in his team has a defined role. Roux himself manages all gene bank related activities such as for example, collecting new varieties in Papua New Guinea where a team member (Julie Sardos geneticist) is working with national partners to collect seeds of wild bananas to safeguard the diversity. Everything is conserved in test tubes at ITC where Roux goes once every two or three months.

About 70% of the samples are cryo preserved with three copies. The third copy is kept in Montpellier, in case there is a disaster in Belgium. The technology is working so well we are proposing to have a backup for allvegetative propagated crops which are maintained in Svalbard. We will most likely complement this with a facility in Belgium, added Roux.

CGIAR arose in response to widespread concern in the mid-20th century that rapid increases in human populations would lead to widespreadfamine.

Part of this movement saw work by Norman Borlaug (1914-2009), the Rockerfeller Foundation and the Mexican government promoting the Green Revolution, which led to the establishment of theInternational Rice Research Institute(IRRI) in 1960 andInternational Maize and Wheat Improvement Center(CIMMYT) in 1963, developing high-yielding, disease-resistant varieties that dramatically increased production of these staple cereals.

Svalbard Global Seed Vault

Borlaug developed semi-dwarf, high-yield,disease-resistantwheatvarieties and in the mid-20th century, he led the introduction of these high-yielding varieties combined with modern agricultural production techniques to Mexico, Pakistan and India. As a result, Mexico became a net exporter of wheat by 1963. Between 1965 and 1970, wheat yields nearly doubled in Pakistan and India, improving food securityin those nations, said Roux

Borlaug was often called 'the father of the Green Revolution' and is credited with saving over a billion people worldwide from starvation.

In 1970, the Rockefeller Foundation proposed a worldwide network of agricultural research centers under a permanent secretariat. This was further supported and developed by theWorld Bank, FAO and UNDP, and CGIAR was established on May 19, 1971, to coordinate international agricultural research efforts at reducing poverty and achievingfood securityin developing countries.

CGIAR originally supported four centres: CIMMYT;IRRI; theInternational Center for Tropical Agriculture(CIAT); and theInternational Institute of Tropical Agriculture(IITA).

The initial focus was on rice, wheat and maize which was extended to cassava, chickpea, sorghum, potato, millet and other food crops.

By the 1990s the number of centers supported by CGIAR had grown to 18 but thanks to mergers with theInternational Laboratory for Research on Animal Diseases(ILRAD) and theInternational Livestock Centre for Africa(ILCA) and the absorption of work on bananas and plantains into the program of theInternational Plant Genetic Resources Institute(IPGRI); nowBioversity International, the number went to 16 then 15 after it merged another center (ISNAR).

CGIAR has 15 centres around the world and underwent several reforms in 2012. We receive funds from different countries but instead of working in silos, we wanted to develop programmes across all the centres. For example, I work on biodiversity in one of the programmes involved, preserving the biodiversity of several crops such as rice, wheat, maize, cassava, sweet potato and bananas, working closely with the FAO (Food and Agriculture Organization of the United Nations), added Roux.

For food security the investors want to see the impact our work is having on reducing hunger but we need more longterm funding for that."

The inauguration of the CGIAR System Organization headquarters took place in Montpellier, France on the Agropolis International site in 2014. Having decided to move office from Washington DC in the US to Montpellier in 2012.

The big news now is that our cryo-preservation technology is working so well that we are proposing to house a backup for the Svalbard Global Seed Vault, on the Norwegian island of Spitsbergen.

Almost one million seed samples from all over the world are stored at the Svalbard Global Seed Vault, which opened in 2008. The vault's purpose is to save humanity in the event of a major global disaster.

Here is the original post:
Fusarium disease: Researchers race to save bananas from extinction - FoodNavigator.com

Posted in New Mexico Stem Cells | Comments Off on Fusarium disease: Researchers race to save bananas from extinction – FoodNavigator.com

OSU professor injured in bike wreck feels lucky to be alive – Norman Transcript

Posted: October 30, 2019 at 1:42 pm

STILLWATER, Okla. Udaya DeSilva doesnt remember exactly how he wound up in the hospital. He lost at least 45 minutes on the evening of Oct. 14 when he was struck by a pickup while riding his bike.

The Oklahoma State University professor of animal molecular genetics was wrapping up a 10-mile ride and was only a mile from home.

He remembers starting to go up the hill on Lakeview Road as it crosses Boomer Lake. The next thing he knew, he was waking up in Stillwater Medical Centers emergency department.

He says considering the situation, thats probably for the best.

Now 17 days later, hes about to go home. But hes still got a long road to travel before hes back to normal.

DeSilva is going home in a back brace and using a walker after suffering a compression fracture in his back, a dislocated hip, a separated shoulder, a fracture in his right hand, a Grade 3 concussion and superficial injuries all the way down his right side. He says he lost about four units of blood.

Hes facing months of recovery and physical therapy.

But in spite of the extent of his injuries, DeSilva feels fortunate. The picture would probably have been different if he hadnt been wearing his helmet.

All of this is going to take time, but its 100% fixable, he said. If I was not wearing a helmet, I would be dead.

He bases that conclusion on the amount of damage the back of his helmet sustained.

DeSilva expects to make a full recovery and to eventually be back on his bike. Its something he grew up doing in Sri Lanka and has continued to do through his 30 years in the U.S.

He spends a lot of time on a bike, using it to commute to work work most days.

There were a few times he says it seemed like drivers got a little too close, but he doesnt usually feel unsafe on the road. He had one experience where a driver screamed at him.

DeSilva says that Stillwater has become much more bike-friendly in the past 10 years. But there is obviously room for improvement.

Multiple witnesses said the driver who struck him failed to provide at least three feet of clearance around his bike as state law requires.

Although the accident report notes that as a contributing factor, it doesnt indicate that the driver received a citation. An inquiry to the Stillwater Police Department about it hadnt received a response by press time.

DeSilva is a believer in having the proper safety equipment, now more than ever.

You take precautions, you do whatever you can, but things like this happen, he said. One thing I want people to know is: Wear a helmet.

Oklahome Bike Laws

Under Oklahoma Title 47, motorists are required to allow at least three feet of space between their vehicle and a bicycle they are passing or overtaking.

The penalty for violating that law, if it results in a collision causing serious physical injury, is a fine of up to $500.

If the collision causes the death of another person, the fine rises to $1,000, in addition to other penalties prescribed by law.

Bicycles are considered vehicles under Oklahoma law. They have the right to travel on the roadway, even if they cant travel as fast as other traffic.

They are only allowed to ride two abreast and should ride single file on roads divided into lanes.

If a usable bike path is provided, local ordinances can require bicyclist to ride on that path instead of the road.

Bicycles traveling slower than the normal speed of traffic must ride as close as possible to the right-hand curb unless they are passing, turning left or avoiding objects and hazards.

Front and rear lights and reflectors are required while on streets or highways with a speed limit over 25 miles per hour.

By the Numbers:

The NHTSA overview report for 2018 shows that fatalities for occupants of every type of motorized vehicle except large trucks decreased from 2017 to 2018. Fatalities for nonoccupant pedestrians and cyclists increased during that same period.

A reported 857 cyclists died in 2018, a 6.3% increase and the highest number since 1990.

Charles writes for Stillwater News Press, a CNHI News Service publication.

Here is the original post:
OSU professor injured in bike wreck feels lucky to be alive - Norman Transcript

Posted in Molecular Genetics | Comments Off on OSU professor injured in bike wreck feels lucky to be alive – Norman Transcript

Comments Sought in Regular Review of Vice President for Finance and Treasurer Tim Walsh – Duke Today

Posted: October 30, 2019 at 1:42 pm

A university committee is seeking comments as part of a regular performance review of Vice President for Finance Tim Walsh. Reviews of senior administrators are typically conducted in the fourth year of a five-year term, and the results complied in a confidential report.

This will be the second such review for Walsh, who has served in his current post since 2011.

Executive Vice President Tallman Trask asked Peter Feaver, professor of Political Science, to chair the committee. Other members are: Kerry Abrams (School of Law); Billy Newton (School of Medicine); Scott Greenwood (Duke University Alumni Association); Joanna Rojas (Office of Audit, Risk and Compliance); Beth Sullivan (Professor of Molecular Genetics and Microbiology); and Laura Meyer Wellman (Board of Trustees).

Walsh joined Duke in 2004 as assistant vice president and controller. In 2011, he was promoted to vice president for finance, where he oversees an array of accounting, reporting and financial functions, including the treasury, budgeting, procurement, real estate, stores and licensing, administrative systems, research costing and compliance, auxiliaries finance and controller's functions.

At Duke, Walsh has, among other things, co-chaired efforts to streamline core financial and administrative processes that support the university's international activities; chaired the Research Administration Continuous Improvement (RACI) initiative, which promotes the efficient and effective administration of Duke's $1.1 billion research enterprise; and overseen the implementation of monthly reporting processes that provide greater transparency of the university's comprehensive financial performance to executive administrators and trustees.

An important part of the review process is the gathering of opinions from the universitys many constituencies. Comments on performance and suggestions for the future are important to the committees work. Communication should include the nature of interactions with Walsh and his team so that the committee can best understand the context of the comments.

The committee will discuss responses and a summary will be included in the written report to the executive vice president. The committee will hold all communication in strict confidence.

Comments should be submitted by Nov. 8, 2019. Please send any communications to:

Peter Feaver, Chair

Walsh Review Committee

Box 90204

Durham, North Carolina 27708

admin-review@duke.edu

Read the rest here:
Comments Sought in Regular Review of Vice President for Finance and Treasurer Tim Walsh - Duke Today

Posted in Molecular Genetics | Comments Off on Comments Sought in Regular Review of Vice President for Finance and Treasurer Tim Walsh – Duke Today

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting – BioSpace

Posted: October 30, 2019 at 1:42 pm

SALT LAKE CITY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that it will present results from seven studies at the 2019 National Society of Genetic Counselors (NSGC) annual meeting being held Nov. 58, 2019 in Salt Lake City.

"We are excited to present new data from seven studies at this years NSGC meeting," said Susan Manley, MS, CGC, MBA, senior vice president of Medical Services at Myriad Genetics. Our presentations highlight the companys commitment to advancing precision medicine in oncology and womens health.

A list of presentations at 2019 NSGC is below. Please visit Myriad Genetics at booth #711 to learn more about our leading portfolio of precision medicine products. Follow Myriad on Twitter via @myriadgenetics and follow meeting news by using the hashtag #NSGC19.

myRiskHereditaryCancer

ForesightCarrierScreen

AishwaryaArjunan

PrequelTMPrenatalScreen

About Myriad myRisk Hereditary CancerThe Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

AboutForesight Carrier ScreenThe Myriad Foresight Carrier Screen is designed to maximize detection of at-risk couples for serious, prevalent, and clinically-actionable conditions. Foresight has a rigorous disease selection that focuses on 175+ conditions that provides meaningful information to patients. Additionally, Foresight offers superior technology with unmatched detection rates for the vast majority of genes on the panel (>99% across ethnicities) which means patients can trust both positive and negative results.

About PrequelTM Prenatal ScreenThe Myriad Prequel Prenatal Screen is a noninvasive prenatal screen that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for chromosome abnormalities, such as Down syndrome. Prequel has been shown to be superior to screening methods that use maternal age, ultrasound and serum screening. Additionally, Prequel has a lower false-positive rate and false-negative rate than these other methods. The Prequel Prenatal Screen can be ordered with the Foresight Carrier Screen and offered to all women, including those with high body mass index, and ovum donor or a twin pregnancy.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to data being presented for its genetic tests at the 2019 National Society of Genetic Counselors Meeting being held Nov. 58, 2019 in Salt Lake City; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

See the original post here:
Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting - BioSpace

Posted in Molecular Genetics | Comments Off on Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting – BioSpace

Researchers find new organelle that may help cancer patients – CBS19 News

Posted: October 30, 2019 at 1:42 pm

CHARLOTTESVILLE, Va. (CBS19 NEWS) -- Scientists looking for a way to help breast cancer patients have found a new organelle inside cells that may help.

Researchers at the University of Virginia School of Medicine say the organelle works to prevent cancer by ensuring that genetic material is sorted correctly as cells divide and problems with this organelle have been connected to a subset of breast cancer tumors due to a lot of mistakes when segregating chromosomes.

According to a release, this analysis offers a new way for doctors to sort patient tumors as they choose the therapies that may be used to treat the patients.

The researchers hope these insights will help doctors to better personalize treatments to best benefit patients, potentially sparing up to 40 percent of breast cancer patients from treatment that will not be effective.

Some percentage of women get chemotherapy drugs for breast cancer that are not very effective. They are poisoned, in pain and their hair falls out, so if it isn't curing their disease, then that's tragic, said researcher P. Todd Stukenberg, PhD, of the UVA Department of Biochemistry and Molecular Genetics. One of our goals is to develop new tests to determine whether a patient will respond to a chemotherapeutic treatment, so they can find an effective treatment right away.

Stukenberg and his team of researchers ay the organelle they found is essential but ephemeral, as it only forms when needed to ensure chromosomes are sorted correctly. It then disappears when that task is complete.

Stukenberg also compares the organelle to a droplet of liquid that condenses within other liquid, saying the droplets act like mixing bowls that concentrate certain cellular ingredients to allow for biochemical reactions to occur in a specific location.

What's exciting is that cells have this new organelle and certain things will be recruited into it and other things will be excluded, he said. The cells enrich things inside the droplet and, all of a sudden, new biochemical reactions appear only in that location. It's amazing.

He says the organelle acts more like a gel that allows cellular components to come in and exit but it has binding sites that concentrate a small set of the cell's contents.

Our data suggests this concentration of proteins is really important, said Stukenberg. I can get complex biochemical reactions to occur inside a droplet that I've been failing to reconstitute in a test tube for years. This is the secret sauce I've been missing.

The release adds that researchers have known for about eight years that cells make droplets like this for other processes, but they did not know they are made on chromosomes during cell division.

Stukenberg thinks such droplets are common and more important than previously understood, saying the cells are using these non-membranous organelles to regulate much of their work.

The release says this discovery helps scientists better understand the process of mitosis, or cell division, and it sheds light on cancer and how it occurs.

The organelle's main function is to fix mistakes in tiny microtubules that pull apart chromosomes when cells are dividing. They ensure that each cell gets the correct genetic material.

However, in cancer cells, the repair process is defective, and the cancer cells can be driven to be more aggressive.

Stukenberg has also developed tests to measure the amount of chromosome mis-segregation in tumors, which he hopes will allow doctors to pick the proper treatment for patients.

His next step he says will be to examine the strange organelle's role in colorectal cancer.

The findings have been described in the scientific journal Nature Cell Biology.

See original here:
Researchers find new organelle that may help cancer patients - CBS19 News

Posted in Molecular Genetics | Comments Off on Researchers find new organelle that may help cancer patients – CBS19 News

Page 1,294«..1020..1,2931,2941,2951,296..1,3001,310..»